3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
9
Gynecologic
2
Head & Neck
1
Conditions
Endometrial Neoplasms
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Breast Diseases
1
Interventions
pembrolizumab
33
Paclitaxel
27
Cyclophosphamide
25
Carboplatin
23
olaparib
21
Fulvestrant
15
fludarabine
14
Trastuzumab
14
aldesleukin
13
Docetaxel
13
Early Intervention, Educational
12
Surveys and Questionnaires
11
veliparib
10
palbociclib
10
Methods
10
Gemcitabine
10
Blood Specimen Collection
10
Nivolumab
9
Flow Cytometry
9
Biopsy
9
Bevacizumab
9
sargramostim
8
niraparib
7
liposomal doxorubicin
7
Therapeutics
7
Taxes
7
Standard of Care
7
Psychiatric Rehabilitation
7
Magnetic Resonance Spectroscopy
7
talazoparib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Imlunestrant
×
Gynecologic
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT04188548
2025-06-04
EMBER
Eli Lilly and Company
Phase 1
Active not recruiting
500 enrolled